• search

Antibiotic safely treats chlamydia in pregnancy

Written by: Staff

NEW YORK Mar 31 (Reuters) A study of pregnant women with chlamydia, a sexually transmitted disease, shows that the antibiotic azithromycin is highly effective with no significant adverse effects on mother or infant, physicians at the University of California at San Francisco report.

Dr Lisa Rahangdale and colleagues took a look back at 227 pregnant women with genital chlamydial infection. Most of the women (69 percent) received treatment with azithromycin; 19 percent and 9 percent received two other antibiotics -- erythromycin and amoxicillin, respectively. The remaining women received other drug regimens.

Treatment efficacy was 97 percent in the azithromycin group, 64 percent in the erythromycin group and 95 percent in the amoxicillin group, as evidenced by a negative test of cure 7 or more days after diagnosis and again before delivery.

Efficacy did not vary by age, ethnicity (more than half of patients were black and Hispanic) the presence of another sexually transmitted disease, partner's treatment or substance use.

There was no difference in rates of adverse events among the treatment groups in either women or their infants.

''Considering the serious consequences of preterm labor and perinatal infection, it is important to treat pregnant women with the most efficacious regimen in pregnancy,'' the authors write in the journal Sexually Transmitted Diseases.

Based on their findings, they conclude that ''azithromycin should be considered as a first-line agent for the treatment of chlamydia during pregnancy.'' REUTERS SK RN0430

For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more